1. Home
  2. GANX vs RECT Comparison

GANX vs RECT Comparison

Compare GANX & RECT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • RECT
  • Stock Information
  • Founded
  • GANX 2017
  • RECT 1997
  • Country
  • GANX United States
  • RECT Singapore
  • Employees
  • GANX N/A
  • RECT N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • RECT
  • Sector
  • GANX Health Care
  • RECT
  • Exchange
  • GANX Nasdaq
  • RECT Nasdaq
  • Market Cap
  • GANX 57.9M
  • RECT 66.1M
  • IPO Year
  • GANX 2021
  • RECT 2024
  • Fundamental
  • Price
  • GANX $1.93
  • RECT $4.80
  • Analyst Decision
  • GANX Strong Buy
  • RECT
  • Analyst Count
  • GANX 5
  • RECT 0
  • Target Price
  • GANX $8.20
  • RECT N/A
  • AVG Volume (30 Days)
  • GANX 226.2K
  • RECT 9.5K
  • Earning Date
  • GANX 05-14-2025
  • RECT 03-27-2025
  • Dividend Yield
  • GANX N/A
  • RECT N/A
  • EPS Growth
  • GANX N/A
  • RECT N/A
  • EPS
  • GANX N/A
  • RECT 0.14
  • Revenue
  • GANX N/A
  • RECT $33,502,767.00
  • Revenue This Year
  • GANX N/A
  • RECT N/A
  • Revenue Next Year
  • GANX N/A
  • RECT N/A
  • P/E Ratio
  • GANX N/A
  • RECT $33.72
  • Revenue Growth
  • GANX N/A
  • RECT 8.42
  • 52 Week Low
  • GANX $0.89
  • RECT $2.70
  • 52 Week High
  • GANX $3.19
  • RECT $7.68
  • Technical
  • Relative Strength Index (RSI)
  • GANX 53.25
  • RECT N/A
  • Support Level
  • GANX $1.80
  • RECT N/A
  • Resistance Level
  • GANX $1.85
  • RECT N/A
  • Average True Range (ATR)
  • GANX 0.13
  • RECT 0.00
  • MACD
  • GANX -0.00
  • RECT 0.00
  • Stochastic Oscillator
  • GANX 60.00
  • RECT 0.00

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About RECT Rectitude Holdings Ltd Ordinary Shares

Rectitude Holdings Ltd is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, hand gloves, safety footwear, and personal fall arrest systems (a system used to arrest an employee in a fall from a walking-working surface, usually consisting of a body harness, anchorage, and connector), portable fire extinguishers and traffic products such as rubber speed humps, wheel stops and wheel chocks.

Share on Social Networks: